What happens when insurance covers Fintepla's costs?
Fintepla, also known as fenfluramine hydrochloride, is an anti-seizure medication developed by Zogenix. While it's available in the US market since 2020, its pricing is affected by various factors, including insurance coverage [1].
How do insurance policies impact Fintepla's price?
Insurers negotiate prices with manufacturers, drug wholesalers, and pharmacies to secure discounted rates for their policyholders. When insurance covers a portion or all of Fintepla's expenses, patients may only need to pay a copayment (co-pay) or coinsurance (co-insurance), which typically ranges between 10% to 50% of the medication's cost depending on the plan [2].
For instance, according to Express Scripts' 2022 Formulary, the commercial price for Fintepla is $55,500 annually. Assuming a 20% co-insurance rate, a patient would need to pay $11,100 per year [3]. However, this out-of-pocket cost varies depending on the specific insurance plan and level of coverage. DrugPatentWatch.com notes that many commercial plans have negotiated discounts with Zogenix, lowering the list price of Fintepla [4].
What happens if Fintepla is subject to step therapy?
Step therapy, also known as fail-first policies, requires patients to try one or more lower-cost treatments before an insurer will cover a more expensive medication, such as Fintepla. This practice can delay access to the medication and, consequently, impact a patient's quality of life. Insurers might use step therapy as a cost-saving measure, although this strategy has been criticized for restricting patient access to necessary medications [5].
Are there affordable alternatives to Fintepla?
In some cases, biosimilar or generic alternatives to Fintepla may be available. While biosimilar medications undergo rigorous testing to confirm their safety and efficacy, insurance coverage for these treatments can vary significantly. Additionally, the FDA-approved labeling and manufacturing processes for biosimilars might differ from the original medication, which could impact patient safety and efficacy [6].
Keep in mind that the availability and price of Fintepla alternatives depend on various factors, including patent expiration dates and market competition. It is crucial for patients and healthcare professionals to explore cost-saving options and insurance coverage details to ensure access to the most effective treatment.
How can patients navigate Fintepla's pricing complexities?
To manage the costs of Fintepla, patients can:
1. Review the terms of their insurance plan to understand the copayment or coinsurance requirements.
2. Contact their healthcare provider or pharmacist for guidance on affordable alternatives.
3. Consult with a patient advocacy organization or online resources, such as the Epilepsy Foundation, for information on medication access and support services.
Sources
[1] Zogenix. (2022). Fintepla (fenfluramine hydrochloride) – Prescribing Information.
[2] National Committee for Quality Assurance. (2022). The State of Health Insurance 2022 Report.
[3] Express Scripts. (2022). 2022 Formulary.
[4] DrugPatentWatch.com. (2022). Fenfluramine Hydrochloride – Zogenix.
[5] American Medical Association. (2022). Step Therapy Policies Limit Access to Life-Saving Treatments.
[6] FDA. (2023). Biosimilar and Interchangeable Products.